March 2023 Top Biopharma Deal: OncoC4 – BioNTech for ONC-392 for Solid Tumors and NSCLC

By Chris Dokomajilar

Apr 3, 2023

Deal of the month, Partnership Deals

March 2023 Top Biopharma Deal Upfront

OncoC4 co-development and commercialization deal with BioNTech for ONC-392

Highlighted Deal Financial Comps

- Date Announced:
- ,
  March 20, 2023
- Total Deal Value:
- ,
  $200M + Mst
- Upfront Cash:
- ,
  $200M
- Upfront Equity:
- ,
  n/a
- Option Payments:
- ,
  n/a
- Total Milestones:
- ,
  Undisclosed dev., reg., and sales milestones
- Royalties:
- ,
  Undisclosed tiered double-digit royalties
- Cost & Profit Split:
- ,
  50% development cost split

Deal Synopsis

- The Asset:
- ,
  OncoC4’s ONC-392 anti-CTLA-4 monoclonal antibody candidate in Phase II as monotherapy or in combination with anti-PD1 in various solid tumor indications, including immunotherapy-resistant non-small cell lung cancer (NSCLC).
- Deal Structure:
- ,
  Development and Commercial License
- Partnership Features:
- ,
  Co-Development, Shared Cost
- Deal Details:
- ,
  - OncoC4 granted BioNTech exclusive, worldwide rights to co-develop and commercialize OncoC4’s ONC-392, an anti-CTLA-4 mAb as a monotherapy and in combination with anti-PD-(L)-1 antibodies for the treatment of solid tumors, including NSCLC.
  - OncoC4 and BioNTech will equally share the development costs while OncoC4 will negotiate for the commercialization of therapies in certain territories.
  - OncoC4 will receive $200M up front and is eligible for undisclosed development, regulatory, and commercial milestones, plus tiered double-digit royalties.
- Last Month:
- ,
  
  Congrats to OncoC4 and BioNTech for landing DealForma’s March 2023 Top Biopharma Deal. Last month’s Deal of the Month was Axsome and Pharmanovia deal for Sunosi. Read about it here.
  
  DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
  
  We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

DealForma Research

Endocrine, Metabolic R&D Partnerships, M&A and Ventures by Tech – H1 2024 Review

October 2, 2024

Neurology R&D Partnerships, M&A and Ventures by Tech – Q2 2024 Review

September 25, 2024

Neurology R&D Partnerships, M&A, Ventures and IPOs by TA – Q2 2024 Review

September 18, 2024

All of this by stage, disease indication, modality, target…

+ 0 k

Licensing Deals

+ 0 k

M&A

+ 0 k

Other Deals

+ 0 k

Funding Rounds

+ 0 k

Company Profiles

+ 0 k

Drug Sales Figures